REPLIGEN CORP Business Acquisition, Pro Forma Net Income (Loss)
REPLIGEN CORP (RGEN) reported Business Acquisition, Pro Forma Net Income (Loss) of $9.49 billion for the 12-month period ending 2014-12-31, per its 10-K filed 2016-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2016-02-25
- REPLIGEN CORP business acquisition, pro forma net income (loss) for the quarter ending 2014-12-31 was $9.48B, a 42.14% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma net income (loss) for the quarter ending 2014-09-30 was $1.85M, a 70.01% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma net income (loss) for the quarter ending 2014-06-30 was $3.82M, a 13.11% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma net income (loss) for the quarter ending 2013-12-31 was $16.39B.
- REPLIGEN CORP business acquisition, pro forma net income (loss) for fiscal 2014 was $9.49B, a 42.13% decline from fiscal 2013.
- REPLIGEN CORP business acquisition, pro forma net income (loss) for fiscal 2013 was $16.40B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $9.48B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $9.48B derived: sum of 2 quarters · filed 2016-02-25 | $9.49B derived: sum of 3 quarters · filed 2016-02-25 | $9.49B 10-K · filed 2016-02-25 | $9.49M 10-K · filed 2015-03-17 |
| 2014-09-30 | $1.85M 10-Q · filed 2015-11-05 | $5.67M derived: sum of 2 quarters · filed 2015-11-05 | $9.89M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $3.82M 10-Q · filed 2014-08-11 | $8.00M 10-Q · filed 2014-08-11 | |||
| 2013-12-31 | $16.39B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $16.40B derived: sum of 2 quarters · filed 2016-02-25 | $16.40B derived: sum of 3 quarters · filed 2016-02-25 | $16.40B 10-K · filed 2016-02-25 | $16.40M 10-K · filed 2015-03-17 |
| 2013-09-30 | $6.16M 10-Q · filed 2014-11-07 | $10.56M derived: sum of 2 quarters · filed 2014-11-07 | $12.19M 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $4.39M 10-Q · filed 2014-08-11 | $6.37M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |